1-8 of 8
Aaron S. Mansfield
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Trials, Tribunals, and Opportunities for Lung Cancer KRASG12C Brain Metastases

Anuhya Kommalapati, Aaron S. Mansfield
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (15): 3179–3181.
https://doi.org/10.1158/1078-0432.CCR-22-1137
Published: 02 August 2022
View article titled, Trials, Tribunals, and Opportunities for Lung Cancer <em>KRAS<sup>G12C</sup></em> Brain Metastases
Open the PDF for Trials, Tribunals, and Opportunities for Lung Cancer <em>KRAS<sup>G12C</sup></em> Brain Metastases in another window
Journal Articles

A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non–Small Cell Lung Cancer

Michael R. Shafique, Terrence L. Fisher, Elizabeth E. Evans, John E. Leonard, Desa Rae E. Pastore, Crystal L. Mallow, Ernest Smith, Vikas Mishra, Andreas Schröder, Kevin M. Chin, Joseph T. Beck, Megan A. Baumgart, Ramaswamy Govindan, Nashat Y. Gabrail, Alexander I. Spira, Nagashree Seetharamu, Yanyan Lou, Aaron S. Mansfield, Rachel E. Sanborn, Jonathan W. Goldman, Maurice Zauderer
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (13): 3630–3640.
https://doi.org/10.1158/1078-0432.CCR-20-4792
Published: 01 July 2021
View article titled, A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non–Small Cell Lung Cancer
Open the PDF for A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Nivo-lution in Mesothelioma

Aaron S. Mansfield, Marjorie G. Zauderer
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (18): 5438–5440.
https://doi.org/10.1158/1078-0432.CCR-19-1836
Published: 13 September 2019
View article titled, Nivo-lution in Mesothelioma
Open the PDF for Nivo-lution in Mesothelioma in another window
Journal Articles

Predicting Treatment Response Based on RNA Expression in Large Datasets

Aaron S. Mansfield, Jin Jen
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (5): 1443–1445.
https://doi.org/10.1158/1078-0432.CCR-18-2823
Published: 01 March 2019
View article titled, Predicting Treatment Response Based on RNA Expression in Large Datasets
Open the PDF for Predicting Treatment Response Based on RNA Expression in Large Datasets in another window
Journal Articles

Abstract A17: Establishment of a unique patient-derived tumor model positive for STRN-ALK fusion from a patient with stage IV lung adenocarcinoma

HongZheng Res, XiaoNan Hou, Karlyn E. Pierson, Patric Eiken, Asha Nair, PingYang Yang, Joanne Eunhee Yi, Aaron S. Mansfield, Jin Jen
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (17_Supplement): A17.
https://doi.org/10.1158/1557-3265.AACRIASLC18-A17
Published: 01 September 2018
View article titled, Abstract A17: Establishment of a unique patient-derived tumor model positive for <em>STRN-ALK</em> fusion from a patient with stage IV lung adenocarcinoma
Journal Articles

Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I Trial

Vincent Chung, Aaron S. Mansfield, Fadi Braiteh, Donald Richards, Henry Durivage, Richard S. Ungerleider, Francis Johnson, John S. Kovach
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (13): 3277–3284.
https://doi.org/10.1158/1078-0432.CCR-16-2299
Published: 02 July 2017
View article titled, Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I Trial
Open the PDF for Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I Trial in another window
Journal Articles

The Effect of Hepatic Impairment on Outcomes in Phase I Clinical Trials in Cancer Subjects

Aaron S. Mansfield, Michelle A. Rudek, Diana Vulih, Gary L. Smith, Pamela Jo Harris, S. Percy Ivy
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (22): 5472–5479.
https://doi.org/10.1158/1078-0432.CCR-16-0449
Published: 14 November 2016
View article titled, The Effect of Hepatic Impairment on Outcomes in Phase I Clinical Trials in Cancer Subjects
Open the PDF for The Effect of Hepatic Impairment on Outcomes in Phase I Clinical Trials in Cancer Subjects in another window
Includes: Supplementary data
Journal Articles

Heterogeneity of Programmed Cell Death Ligand 1 Expression in Multifocal Lung Cancer

Aaron S. Mansfield, Stephen J. Murphy, Tobias Peikert, Eunhee S. Yi, George Vasmatzis, Dennis A. Wigle, Marie Christine Aubry
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (9): 2177–2182.
https://doi.org/10.1158/1078-0432.CCR-15-2246
Published: 01 May 2016
View article titled, Heterogeneity of Programmed Cell Death Ligand 1 Expression in Multifocal Lung Cancer
Open the PDF for Heterogeneity of Programmed Cell Death Ligand 1 Expression in Multifocal Lung Cancer in another window
Includes: Supplementary data